Managing GP
SAVA
SAVA is developing a minimally invasive wearable biosensor that continuously monitors multiple biomolecules—including glucose, lactate, ketones, and cortisol—in the interstitial fluid just below the skin. The device streams real-time health data directly to a smartphone app, enabling proactive management of chronic conditions and general wellness. The platform is designed for multi-molecule detection on a single device, with its first application targeting the continuous glucose monitoring market.
- Medical Devices
- Healthcare Technology
- Internet of Things
- Digital Health
- Hardware
- Software Only
- Biotechnology
Updated 2 days ago
Funding
Raised to date
$68MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 3 rounds
ADAVEV+6$36M · Series B
Announced Oct 2026 · from article date
Disclosed cumulative: $63M
3/3
RoundDateAmountValuationInvestors
Founders
Rafaël Michali
Co-Founder
Renato Circi
Co-Founder
Product
Problem
Current methods for monitoring health biomarkers often require invasive procedures or episodic lab tests, limiting the ability to track real-time changes and proactively manage health conditions. Existing wearable sensors typically measure surface-level data, lacking the ability to directly monitor key biomolecules beneath the skin.
Solution
SAVA is developing a minimally invasive biosensing platform that continuously monitors multiple biomolecules just below the skin, providing real-time health data directly to users' smartphones. The sensor technology gathers data from the interstitial fluid, offering insights into glucose, lactate, ketones, sodium, histamine, urea, alcohol, and cortisol levels. This continuous monitoring approach aims to enable proactive management of chronic conditions, improve athletic performance, and provide a more comprehensive understanding of overall well-being. The data is streamed to a connected platform, providing users with effortless access to health insights anywhere, anytime.
Target Audience
Primary target audience includes individuals with diabetes, athletes seeking to optimize performance, and health-conscious individuals interested in proactive health management. The company's initial device focuses on people with diabetes, a population projected to reach 783 million by 2045.
Features
- Minimally invasive microsensing technology that gathers data from interstitial fluid just below the skin, designed for comfortable wear without compromising accuracy
- Multi-molecule detection on a single device, including glucose, lactate, ketones, sodium, histamine, urea, alcohol, and cortisol
- Wireless data transmission to a smartphone app for real-time, effortless access to health insights
- Low-cost design engineered for high-volume manufacturing and affordability, targeting disruption of the $8.2 billion continuous glucose monitoring market
- Modular platform architecture enabling expansion to additional analytes and applications beyond glucose monitoring
- Received MHRA approval to proceed with clinical trials on patients with diabetes, with studies scheduled with investigators from the Universities of Oxford and Cambridge